Denali Therapeutics Inc. (DNLI)
- Previous Close
15.99 - Open
16.14 - Bid 16.08 x 100
- Ask 16.12 x 200
- Day's Range
16.02 - 16.80 - 52 Week Range
15.45 - 33.31 - Volume
1,062,333 - Avg. Volume
1,241,908 - Market Cap (intraday)
2.296B - Beta (5Y Monthly) 1.33
- PE Ratio (TTM)
-- - EPS (TTM)
-1.06 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
41.19
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
www.denalitherapeutics.comRecent News: DNLI
Performance Overview: DNLI
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DNLI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DNLI
Valuation Measures
Market Cap
2.29B
Enterprise Value
1.31B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.69
Price/Book (mrq)
2.22
Enterprise Value/Revenue
3.97
Enterprise Value/EBITDA
-7.29
Financial Highlights
Profitability and Income Statement
Profit Margin
-43.94%
Return on Assets (ttm)
-9.40%
Return on Equity (ttm)
-14.01%
Revenue (ttm)
330.53M
Net Income Avi to Common (ttm)
-145.22M
Diluted EPS (ttm)
-1.06
Balance Sheet and Cash Flow
Total Cash (mrq)
1.03B
Total Debt/Equity (mrq)
5.07%
Levered Free Cash Flow (ttm)
-298.35M